Newsroom
Strive to Deliver Breakthroughs
-
August 28, 2024
Harbour BioMed Announces 2024 Interim Results
Harbour BioMed (“HBM”, or the "Company”; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and c...
View more -
July 26, 2024
Harbour BioMed to Present the Latest Progress of the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024
Cambridge, MA, Rotterdam, NL, Suzhou, CN — July 25, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View more -
July 19, 2024
Harbour BioMed Announces Positive Profit Alert for 2024 Interim Results
Cambridge, MA, Rotterdam, NL, Suzhou, CN – July 19, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View more -
June 27, 2024
Harbour BioMed Announces Resubmission of Biologics License Application for Batoclimab to NMPA for Treatment of Generalized Myasthenia Gravis
Cambridge, MA, Rotterdam, NL, Suzhou, CN – June 27, 2024 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...
View more -
May 23, 2024
Nona Biosciences Announces Global License and Option Agreement with AstraZeneca for Monoclonal Antibody to be Developed into Novel Tumor Targeted Therapies
Nona Biosciences (a wholly-owned subsidiary of HBM Holdings Limited, HKEX: 02142) , a global biotechnology company providing a total solution from “Idea ...
View more -
March 28, 2024
Harbour BioMed Reports Full Year 2023 Financial Results
Cambridge, MA, Rotterdam, NL, Suzhou, CN — March 28, 2024 Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharma...
View more -
January 24, 2024
Harbour BioMed Announces IND Clearance for HBM9027 in the U.S.
Cambridge, MA, Rotterdam, NL, Suzhou, CN Harbour BioMed (the “Company”, HKEX: 02142) announced that the Company has been granted the c...
View more -
January 19, 2024
Harbour BioMed Announces Positive Profit Alert
Cambridge, MA, Rotterdam, NL, Suzhou, CN – Jan 19, 2023 Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical c...
View more -
December 15, 2023
Harbour BioMed's Wholly-owned Subsidiary Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)
Harbour BioMed's Wholly-owned Subsidiary, Nona Biosciences, announced today that it has entered into an exclusive license agreement with Pfizer Inc. for th...
View more -
August 28, 2023
Harbour BioMed Announces 2023 Interim Results
Cambridge, MA, Rotterdam, NL, Suzhou, CN - August 28, 2023 Harbour BioMed (“HBM”, or the "Company”; HKEX: 02142), a global ...
View more
Copyright © 2024 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号
沪ICP备19015946号-1